Genesys Capital invests in and builds companies in the high-growth sectors of biotechnology, pharmaceuticals and medical technology. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies. That track record is fuelled by robust industry relationships, broad business expertise, and a deep understanding of the life sciences sector.
Genesys has generated more than 18 exits from 36 portfolio companies and has invested more than $200M. Our third institutional fund is closed and we’re actively considering new, high-potential life science companies for investment.